Background. Up to 44% of women who experience a urinary tract infection (UTI) develop a recurrent infection (rUTI) within one year. Insufficient evidence about risk factors for recurrence limits clinicians' ability to identify women at risk for rUTI who may benefit from further interventions.
Background. The optimal approach for treating outpatient male urinary tract infections (UTI) is unclear. We studied the current management of male UTI in private outpatient clinics, and evaluated antibiotic choice, treatment duration, and the outcome of recurrence of UTI.
Methods. Visits for all male patients 18 years of age and older during 2011-2015 with ICD-9 Codes for UTI or associated symptoms were extracted from the EPIC Clarity Database of two family medicine, two urology and one internal medicine clinics. For each eligible visit in which an antibiotic was prescribed, we extracted data on the antibiotic used, the duration of treatment, recurrent UTI episodes, as well as patient medical and surgical history. Urologic anatomic abnormalities were an exclusion criterion (Figure 1) .
Results. Six hundred thirty-seven eligible visits were included for 573 unique patients (mean age 53.7 (±16.7 years)). Fluoroquinolones (FQs) were the most commonly prescribed class of antibiotic (69.7%), followed by trimethoprim-sulfamethoxazole (TMP-SMX) (21.2%), nitrofurantoin (5.3%) and β-lactams (3.8%). Use of FQ was lower in the age group of 55 years and above than <55 years (65.4% vs. 74.6% respectively, P < 0.01). Visits in the urology department were less likely to be treated with TMP-SMX, but more likely to be treated with a β-lactam. Those with a higher Charlson Comorbodity Index were more likely to be treated with β-lactams. Nitrofurantoin use was higher for men 55 years of age and above compared with those younger (7.4% and 3% respectively, P <0.01). Overall, the rate of recurrence was 5.6%. Recurrence was not significantly different between longer (>7 days) and shorter (≤7 days) treatments. In the multiple regression analysis, predictors of longer treatment duration included presence of complicating factors (pyelonephritis, nephrolithiasis or prostatitis), use of nitrofurantoin or β-lactams, and visits seen in urology. The presence of fever, diabetes, and BPH, as well as patient race, were not associated with antibiotic choice or treatment duration.
Conclusion. Men with UTIs are most frequently prescribed FQ. Providers' choice of antibiotic was influenced by patient age and comorbidities, while treatment duration was influenced by presence of complicating factors. Background. A significant percentage of patients admitted to the hospital with UTI are infected with ESBL positive and quinolone-resistant (FQ NS) enterobacteriaceae (ENT) that can complicate patient outcomes due to potentially inadequate antibiotic therapy. We used a large national multicenter database to ascertain the demography associated with susceptible and resistant UTI and the underlying comorbidities.
Methods. We analyzed the first positive ENT urine culture ≤3 days from admission in those with a discharge primary or secondary UTI ICD10 code from 68 US hospitals from October 1, 2015-2017 (BD Insights, Franklin Lakes, NJ). Patient demographics were identified using AHRQ classifications to assess for specific risk factors and categorized by ESBL and FQ resistance status. Healthcare-associated (HCA) episodes were defined as admissions from another care facility, admission in the prior 30 days, and presence of dialysis or cancer comorbidity. The Fisher's exact test was used to test for significance.
Results. Of 16,022 adults (mean age 69.5 years; 77.7% female) with culture positive ENT UTI were identified; 11.0% (n = 1,763) were ESBL +, 31.3% (n = 5,017) were FQ NS and 8.9% (n = 1,433) being both ESBL + and FQ NS. Admissions with ESBL + /FQ NS were significantly more likely to be male, admitted with HCA risk factors and with higher important comorbidities. Background. Urinary tract infection (UTI) is a common post-kidney transplant complication that has been associated with risk for allograft dysfunction. However, prior studies assessing risk factors for recurrent post-transplant UTI (rUTI) did not distinguish between asymptomatic bacteriuria and UTI. We hypothesize that early asymptomatic bacteriuria (EAB) and UTI after renal transplant are risk factors for rUTI.
Methods. A single-center retrospective cohort study of renal transplant recipients at a tertiary care, academic medical center from May 1, 2010 to January 31, 2015. Data on epidemiology, comorbidities, donor cultures, number of UTIs, days of foley catheter use, and antibiotic therapy were obtained from the electronic medical record and transplant patient database. Inclusion criteria: >18 years old post kidney transplant during the study period. Exclusion criteria: rUTI prior to transplant or anatomical abnormality of native kidney(s). Definitions: Early post-transplant (EPT): <28 days after transplant. Positive culture: growth of >10 5 cfu/mL. UTI-(fever, dysuria, +/− allograft or suprapubic pain) + positive culture. EAB-asymptomatic bacteriuria in the EPT period. rUTI: ≥ 3 UTIs in 1 year or 2 UTIs in 6 consecutive months within the year post-transplant. UTI episodes were considered separate if occurred >3 weeks after completion of prior antibiotics. Data were analyzed by Fischer's exact test and chi-square test.
Results. A total of 369 patients were included; 40.4% had EAB and 6% had a UTI in the EPT (eUTI). rUTI occurred in 5.7% of patients (n = 21). In the rUTI group, 8 (38.1%) had EAB, 8 (38.1%) had eUTI, and 5 (23.8%) had neither (P = 0.067). rUTI developed in 5.3% (8/149) of the EAB group vs. 36.4% (8/22) of the eUTI group (P < 0.005). No other variables were associated with rUTI. Total UTI episodes was greater with eUTI than EAB (mean 2.09 vs. 0.28, 95% CI 2.2-1.4, P < 0.005).
Conclusion. Only eUTI increased the risk for rUTI. Although screening for bacteriuria is a common practice post-transplant, our data indicates that aggressive symptom screening would better predict likelihood of rUTI and in turn graft dysfunction. Future studies should address the potential benefit of prolonged prophylactic trimethoprim/sufamethoxazole in preventing rUTI.
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Association of Antibiotic Treatment Duration with First Recurrence of Uncomplicated Urinary Tract Infection in Pediatric Patients
Titilola M. Afolabi, PharmD, BCPS, BCPPS; Kellie J. Goodlet, PharmD, BCPS and Kathleen A. Fairman, MA; Midwestern University, Glendale, Arizona Friday, October 5, 2018: 12:30 PM Background. The optimal antibiotic (ABX) treatment duration for uncomplicated urinary tract infection (UTI) in pediatric patients is unknown. The objective of this study was to investigate the association of pediatric UTI treatment duration (7, 10, or 14 days) with infection recurrence or progression.
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Methods. A retrospective cohort analysis of pediatric patients aged 2-17 years with first cystitis or pyelonephritis and without renal/anatomic abnormality was performed using claims and eligibility data from Truven Health MarketScan Database for 2013-2015. Parenteral ABX use and treatment of cystitis diagnosis only were covariates. Relapse and reinfection were defined a priori as UTI diagnosed from, respectively, 0-14 days and 15-30 days following ABX depletion; recurrence was defined as either relapse or reinfection. Progressing infection was defined as recurrence diagnosis of pyelonephritis in a patient originally diagnosed with cystitis only.
Results. Of 7,698 pediatric patients (43.8% aged 2-10 years; 56.2% aged 11-17 years), 85.5% had cystitis and 14.3% pyelonephritis. Duration of ABX treatment included: 3-5 days for cystitis only (20.4%), or 7 (33.6%), 10 (44.2%), or 14 (1.8%) days for any UTI. Recurrence and progressing infection occurred in 5.5% and 0.2% of patients, respectively. Covariates associated with increased recurrence risk included pre-treatment ABX exposure (OR = 1.29; 95% CI = 1.06-1.57); pyelonephritis on diagnosis date (OR = 1.44; 95% CI = 1.03-2.00); follow-up visit during ABX treatment (OR = 3.21; 95% CI = 2.20-4.68); parenteral ABX (OR = 1.89, 95% CI = 1.33-2.69); use of nitrofurantoin (NFT) only (OR = 1.34, 95% CI = 1.00-1.92); and interaction of NFT with pyelonephritis diagnosis (OR = 3.68, 95% CI = 1.20-11.29). After adjustment for measured confounders, the association between duration of ABX treatment and recurrence was not significant (compared with 7 days, 10 days: OR = 1.07, 95% CI = 0.85-1.33; compared with 7 days, 14 days: OR = 0.89, 95% CI 0.45-1.78).
Conclusion. In a national cohort of pediatric patients with uncomplicated UTI, rates of recurrence after ABX depletion did not significantly differ among treatment durations of 7, 10, and 14 days. Results provide support for, without definitively establishing efficacy of, shorter-course ABX treatment.
Disclosures. Friday, October 5, 2018: 12:30 PM Background. The ED environment makes proactive collection of urine cultures (UCs) favorable. However, unnecessary UCs can result in over-detection and over-treatment of asymptomatic bacteriuria (ASB). A previous analysis at the study facility found that UCs were collected frequently despite negative urinalyses (UA), which commonly resulted in unnecessary antibiotics. Our objective was to compare the frequency of inappropriate UC utilization and inappropriate antibiotic prescribing post implementation of a "Urinalysis to Reflex Culture" process change intervention. A secondary objective was to assess the frequency of health encounters for UTIs post implementation.
Methods. After education, an ED process change was implemented in October 2017. This included automatic UC cancellation if UAs had <5 WBC/HPF. An option for "do not cancel (DNC)" UC was available for specific conditions (eg. pregnancy) per guidelines. Data were prospectively collected for 3 months post-implementation and included UA/UC results, presence of UTI symptoms, antibiotics prescribed and healthcare utilization. Inappropriate UC was defined as a UC ordered despite negative UA in asymptomatic patients. Inappropriate antibiotic prescribing was defined as treatment in patients with ASB. A Student's t-test and contingency tables were applied in SAS; significance was set at P ≤ 0.05.
Results. There were 684 UAs (37.2% post-intervention) evaluated from ED visits. Post-intervention (n = 255 UAs), 37.3% of UAs were negative with UCs cancelled. Of the remaining UAs, 37.3% were positive with a processed UC, 16.9% were ordered as DNC and 8.6% were ordered without a UC. UC processing despite a negative UA significantly decreased from 100% pre-intervention to 38.6% post-intervention (P < 0.001). Inappropriate antibiotics for ASB also decreased from 10.2% pre-intervention to 1.9% post-intervention (OR = 0.17; P < 0.0110). In patients with negative UAs, antibiotic prescribing decreased by 25.3% post-intervention (P = NS). No reports of outpatient, ED, or hospital visits for UTI symptoms were found within 7 days of initial UA post-intervention.
Conclusion.
A "UA to Reflex Culture" process change demonstrated a significant decrease in processing of inappropriate UCs and unnecessary antibiotics for ASB. There were no missed UTIs or other adverse patient outcomes.
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